Publications - OpenBiome

2023

Fecal Microbiota Transplantation For Clostridioides Difficile Infection In Immunocompromised Pediatric Patients Opens a new window

Conover KR, Absah I, Ballal S, Brumbaugh D, Cho S, Cardenas MC, Knackstedt ED, Goyal A, Jensen MK, Kaplan JL, Kellermayer R, Kociolek LK, Michail S, Oliva-Hemker M, Reed AW, Weatherly M, Kahn SA, Nicholson MR. FECAL MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIOIDES DIFFICILE INFECTION IN IMMUNOCOMPROMISED PEDIATRIC PATIENTS. J Pediatr Gastroenterol Nutr. 2023 Jan 31. doi: 10.1097/MPG.0000000000003714. Epub ahead of print. PMID: 36720105.

2023

Our Insights

Our Publication Highlights

New & Noteworthy

Fecal Microbiota Transplantation For Clostridioides Difficile Infection In Immunocompromised Pediatric Patients Opens a new window

Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation Opens a new window

Fecal Microbiota Transplantation For Clostridioides Difficile Infection In Immunocompromised Pediatric Patients Opens a new window

Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation Opens a new window

Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans Opens a new window

Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer Opens a new window

Fecal Microbiota Transplantation Improves Gastrointestinal Graft-Versus-Host Disease and Restores the Microbiome: A Pediatric Experience Opens a new window

Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort Opens a new window

HIV-exposure, early life feeding practices and delivery mode impacts on faecal bacterial profiles in a South African birth cohort Opens a new window

Intestinal Microbial and Metabolic Alterations Following Successful Fecal Microbiota Transplant for D-Lactic Acidosis Opens a new window

Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study Opens a new window

Successful Treatment of Fulminant Clostridioides difficile Infection with Emergent Fecal Microbiota Transplantation in a Patient with Acute Myeloid Leukemia and Prolonged, Severe Neutropenia Opens a new window

Fulminant Clostridium difficile Infection Cured by Fecal Microbiota Transplantation in a Bone Marrow Transplant Recipient With Critical Neutropenia Opens a new window

Rapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy Opens a new window

Framework for rational donor selection in fecal microbiota transplant clinical trials Opens a new window

Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial Opens a new window

Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study Opens a new window

Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade Opens a new window

Modelling donor screening strategies to reduce the risk of SARS-CoV-2 transmission via fecal microbiota transplantation Opens a new window

Global disparities in faecal microbiota transplantation research Opens a new window

Gut microbial dysbiosis in individuals with Sjögren’s syndrome Opens a new window

Triclosan has a robust, yet reversible impact on human gut microbial composition in vitro Opens a new window

The impact of gastrointestinal dysmotility on the aerodigestive microbiome of pediatric lung transplant recipients Opens a new window

Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel Opens a new window

Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic Opens a new window

Beyond fecal microbiota transplantation: Developing drugs from the microbiome Opens a new window

Use of Fecal Microbial Transplantation for Immune Checkpoint Inhibitor Colitis Opens a new window

An omics-based framework for assessing the health risk of antimicrobial resistance genes Opens a new window

Carriage rates of multidrug-resistant organisms among prospective stool donors Opens a new window

Fecal microbiota transplantation in HIV: A pilot placebo-controlled study Opens a new window

16S rRNA sequencing of samples from universal stool bank donors Opens a new window

SARS-CoV-2 vaccines and donor recruitment for FMT Opens a new window

Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation Opens a new window

Progressive Shifts in the Gut Microbiome Reflect Prediabetes and Diabetes Development in a Treatment-Naive Mexican Cohort Opens a new window

Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes Opens a new window

Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye Opens a new window

Fecal Microbiota Transplantation (FMT) as an Adjunctive Therapy for Depression-Case Report Opens a new window

Does fecal microbiota transplantation from an obese donor lead to weight gain? A case series of 70 recipients Opens a new window

Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients Opens a new window

Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials Opens a new window

Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity Opens a new window

The Gut Microbiome in Autoimmune Hepatitis Links to Disease Progression and is Significantly Different from Lupus and Healthy Controls Opens a new window

Fecal microbiota transplant using a precision medicine approach is safe, associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathy Opens a new window

Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial Opens a new window

Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant Opens a new window

Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo‐Controlled Trial Opens a new window

Long-term Outcomes after Fecal Microbiota Transplant in Cirrhosis Opens a new window

Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial Opens a new window

Fecal Microbiota Transplantation is Safe and Effective in Patients with Clostridioides difficile Infection and Cirrhosis Opens a new window

Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials Opens a new window

Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo‐Controlled Trial Opens a new window

Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis Opens a new window

A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder Opens a new window

Chronic Liver Diseases and the Microbiome: Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease Opens a new window

Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease Opens a new window

The Risk of Inflammatory Bowel Disease Flares after Fecal Microbiota Transplantation: Systematic Review and Meta-Analysis Opens a new window

Fecal microbiota transplantation differentially influences the gut microbiota of Clostridium difficile infection and ileal pouch anal anastomosis patients Opens a new window

Systematic Review and Meta-Analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis Opens a new window

A Surgical Clostridium-associated Risk of Death Score Predicts Mortality after Colectomy for Clostridium difficile Opens a new window

Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis Opens a new window

Can you cause inflammatory bowel disease with fecal transplantation? A 31-patient case-series of fecal transplantation using stool from a donor who later developed Crohn's disease Opens a new window

Fecal microbiota transplantation is safe and effective in chronic pouchitis patients Opens a new window

The role of fecal microbiota transplantation in ulcerative colitis and Crohn’s disease: results from a parallel inflammatory bowel disease cohort study Opens a new window

Does Rifaximin prior to fecal microbiota transplantation improve clinical outcomes compared to microbiome restoration alone in ulcerative colitis? A cohort study evaluating the impact of non-absorbable antibiotic pretreatment Opens a new window

Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases Opens a new window

The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present and Future Opens a new window

Advances in mesenchymal stromal cell therapy in the management of Crohn's disease Opens a new window

Fecal Microbiota Transplantation in Pouchitis: Clinical, Endoscopic, Histologic, and Microbiota Results from a Pilot Study Opens a new window

Combined Endoscopic and Oral Fecal Microbiota Transplantation in Patients with Antibiotic-Dependent Pouchitis: Low Clinical Efficacy due to Low Donor Microbial Engraftment Opens a new window

Fecal microbiota transplant for Crohn disease: A study evaluating safety, efficacy, and microbiome profile Opens a new window

Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Opens a new window

Re-Evaluating the Evidence for Faecal Microbiota Transplantation ‘Super-Donors’ in Inflammatory Bowel Disease Opens a new window

Fecal transplantation for ulcerative colitis: current evidence and future applications Opens a new window

Fecal Microbiota Transplantation for Ulcerative Colitis. Are We Ready for Primetime? Opens a new window

Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection Opens a new window

Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection Opens a new window

Transferable IgA-coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation Opens a new window